Recurrent cardiotoxicity potentiated by the interaction of proteasome inhibitor and immunomodulatory therapy for the treatment of multiple myeloma.

MLA

Fradley, Michael G., et al. “Recurrent Cardiotoxicity Potentiated by the Interaction of Proteasome Inhibitor and Immunomodulatory Therapy for the Treatment of Multiple Myeloma.” British Journal of Haematology, vol. 180, no. 2, Jan. 2018, pp. 271–75. EBSCOhost, https://doi.org/10.1111/bjh.14970.

APA

Fradley, M. G., Groarke, J. D., Laubach, J., Alsina, M., Lenihan, D. J., Cornell, R. F., Maglio, M., Shain, K. H., Richardson, P. G., & Moslehi, J. (2018). Recurrent cardiotoxicity potentiated by the interaction of proteasome inhibitor and immunomodulatory therapy for the treatment of multiple myeloma. British Journal of Haematology, 180(2), 271–275. https://doi.org/10.1111/bjh.14970

Chicago

Fradley, Michael G., John D. Groarke, Jacob Laubach, Melissa Alsina, Daniel J. Lenihan, Robert F. Cornell, Michelle Maglio, Kenneth H. Shain, Paul G. Richardson, and Javid Moslehi. 2018. “Recurrent Cardiotoxicity Potentiated by the Interaction of Proteasome Inhibitor and Immunomodulatory Therapy for the Treatment of Multiple Myeloma.” British Journal of Haematology 180 (2): 271–75. doi:10.1111/bjh.14970.